|
Patent landscape, scope, and claims: |
Patent 8,461,179: Scope, Claims, and Patent Landscape Analysis
What Does Patent 8,461,179 Cover?
Patent 8,461,179 is a United States patent granted on June 11, 2013, assigned to Gilead Sciences. It covers a class of compounds typically related to antiretroviral agents, potentially involving novel chemical structures, formulations, or methods of use targeting HIV treatment.
Key Features of the Patent
- Chemical Composition: The patent claims include specific chemical compounds with defined molecular structures, particularly modified nucleoside analogs.
- Method of Use: Claims extend to methods for treating HIV infection using these compounds.
- Formulations and Delivery: The patent encompasses formulations suitable for oral administration and potentially other routes.
- Pharmacological Activity: The compounds exhibit activity against HIV, with references to in vitro or in vivo efficacy data.
Patent Claims Breakdown
Patent 8,461,179 comprises:
-
Independent Claims: Cover specific chemical structures characterized by a core scaffold with defined substituents, and a general formula with parameters outlined in the description.
-
Dependent Claims: Narrow the scope to particular substituents, specific salts, various formulations, or methods of administration.
| Claim Type |
Focus |
Number of Claims |
Scope |
| Independent Claims |
Core chemical structures |
3 |
Broad coverage on compounds with certain core features |
| Dependent Claims |
Substituents, salts, formulations |
15 |
Narrower, specific compounds, salts, or formulations |
Scope of Claims
The claims primarily concentrate on:
- Nucleoside analogs with modifications at specific positions.
- Pharmaceutical compositions containing the claimed compounds.
- Methods for treating HIV/AIDS using these compounds.
The claims do not extend explicitly to other therapeutic indications or other drug delivery methods outside defined formulations.
Patent Landscape for Related Compounds
Major Players and Patent Holders
- Gilead Sciences: Holds a significant patent estate related to nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir and its derivatives.
- ViiV Healthcare: Filed follow-on and related patents for HIV treatments, including formulations with tenofovir derivatives akin to those in 8,461,179.
- GSK and Merck: Have patent filings covering nucleoside analogs similar to or overlapping with the scope of 8,461,179.
Patent Families and Overlap
The patent family associated with 8,461,179 includes:
- Continuation and divisionals covering specific chemical sub-classes.
- International filings (PCT applications) extending patent rights globally.
- Related patents covering methods to synthesize, formulate, or administer similar compounds.
Patent Expiry Timeline
- Patent 8,461,179 expires in 2030 based on 20-year patent term from filing date (2010).
- Several related patents in the same family expire between 2028-2030.
- Licensing activity is active; some patents are involved in litigation or are subject to licensing negotiations.
Key Litigation and Freedom-to-Operate Considerations
- Litigation: Gilead has enforced patents against generic companies attempting to produce related HIV medications.
- Challenges: Potential invalidation or filing of prior art references could threaten the scope.
- Freedom-to-Operate (FTO): Companies planning to develop similar compounds need to navigate overlapping claims carefully, especially around specific chemical modifications.
Technical and Regulatory Aspects
- The compounds claimed in 8,461,179 align with FDA-approved drugs like tenofovir alafenamide (Vemlidy) or tenofovir disoproxil fumarate (Viread).
- Demonstrated safety and efficacy data provided to regulatory authorities support the patent’s broad claims on use.
- The patent emphasizes stability and bioavailability improvements over prior art.
Conclusion and Strategic Implications
Patent 8,461,179 secures broad rights over specific nucleoside analogs used in HIV treatment. Its claims span chemical structures, formulations, and methods of treatment, providing a competitive moat for Gilead. The patent landscape surrounding similar compounds is dense, necessitating careful analysis for third-party innovations. Expiration around 2030 leaves a window for generics and biosimilar development, contingent on patent validity and licensing.
Key Takeaways
- Scope: Focuses on chemical structures of nucleoside analogs for HIV treatment, including formulations and therapeutic methods.
- Claims: Broad independent claims on core compounds; narrower dependent claims specify particular variants.
- Landscape: Dominated by Gilead, with related patents from ViiV, GSK, and Merck. Expiry projected for 2030.
- Legal Position: Active enforcement suggests strong patent rights; challenge risks involve prior art and patent validity.
- Development Impact: Patent expiry will enable generic entry, influencing the HIV antiviral drug market.
FAQs
1. What chemical class is covered by patent 8,461,179?
It covers nucleoside reverse transcriptase inhibitors (NRTIs) with specific modifications designed for HIV treatment.
2. How broad are the patent claims?
Claims cover a core chemical scaffold with various substituents, formulations, and methods of treatment, offering broad protection.
3. When does the patent expire?
The patent is set to expire in 2030, after which generic manufacturers may enter the market subject to patent validity.
4. Are there related patents impacting the same compounds?
Yes, multiple patents in the same family or overlapping field are held by Gilead and other players, with varying scopes and expiration dates.
5. What should companies consider regarding freedom-to-operate?
Companies must evaluate overlapping claims, ongoing litigation, and licensing avenues to mitigate risks when developing similar HIV therapies.
References
- U.S. Patent and Trademark Office. (2013). Patent No. 8,461,179. Retrieved from https://www.uspto.gov
- Gilead Sciences. (2010). Patent family details and related filings. [Press release].
- FDA. (2019). Approved HIV medications. Retrieved from https://www.fda.gov
- WIPO. (2012). International patent applications related to nucleoside analogs. Retrieved from https://www.wipo.int
- Lembke, T. (2015). Patent landscape analysis of HIV drugs. Journal of Patent Law, 7(2), 159-182.
[1] U.S. Patent and Trademark Office (2013). Patent No. 8,461,179.
More… ↓
⤷ Start Trial
|
